- Home
- REVG vs ARQT Comparison
REVG vs ARQT Comparison
Compare REVG & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REVG | ARQT |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.3B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REVG | ARQT |
|---|---|---|
| Price | $62.37 | $28.96 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $48.00 | $24.83 |
| AVG Volume (30 Days) | 650.6K | ★ 1.8M |
| Earning Date | 12-10-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $2,463,500,000.00 | $317,929,000.00 |
| Revenue This Year | $9.52 | $85.51 |
| Revenue Next Year | $7.89 | $30.74 |
| P/E Ratio | $33.10 | ★ N/A |
| Revenue Growth | 3.50 | ★ 129.21 |
| 52 Week Low | $26.51 | $11.13 |
| 52 Week High | $64.47 | $31.77 |
Technical Indicators
Market Signals| Indicator | REVG | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 69.10 | 53.65 |
| Support Level | $61.42 | $27.55 |
| Resistance Level | $62.69 | $30.26 |
| Average True Range (ATR) | 1.43 | 1.03 |
| MACD | 0.41 | -0.28 |
| Stochastic Oscillator | 94.26 | 35.15 |
Price Performance
Historical ComparisonAbout REVG REV Group Inc.
REV Group Inc is a United States-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services. During the first fiscal quarter of 2024, the Company formed the Specialty Vehicles Segment by combining the Fire & Emergency and Commercial segment businesses. Additionally, the Recreation segment was renamed Recreational Vehicles. As a result, the Company is now organized into two reportable segments. The company operates in the United States, Canada, and the rest of the world. Maximum of revenue is gained from Specialty Vehicles Segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.